Drugs / Careseng 1370
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03974516 | Aug 2020 → Mar 2022 | myeloid hemopathy | i Cure Biotech Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03692780 | Mar 2019 → Mar 2021 | myeloid hemopathy | Careseng Biotech Co., Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Careseng 1370 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03692780 ↗ |
| Route | Oral | “Careseng 1370 should be taken around 1 hour before meal.” NCT03974516 ↗ |